PDCD1 and melanoma: In this study, we made full use of easily accessible clinicodemographical data together with routinely tested biomarkers from both the complete blood cell and general chemistry tests and developed the first biomarker panels for both survival outcomes and best response, specifically for advanced Asian melanoma patient treated with the anti-PD-1 monotherapy that can facilitate clinical decision making.